Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Amgen Secures FDA Approval for Hormone Drug

Thursday, February 9, 2017   (0 Comments)
Posted by: Kate Oesterle
Share |
  • The Food and Drug Administration has  approved a drug from Amgen designed to regulate a specific group of hormones in patients with chronic kindey disease (CKD) undergoing dialysis, ending a more than 10-year drought for new treatments in that indication.
  • The drug, Parsabiv (etelcalcetide), treats patients with secondary hyperparathyroidism (SHPT), a frequent byproduct of CKD. As the name suggests, SHPT leads to higher levels of parathyroid hormones — molecules responsible for regulating calcium in the blood stream. Notably, patients can receive the drug intravenously.
  • Read full article here.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal